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Borrelia miyamotoi is distantly related to B. burgdorferi 
and transmitted by the same hard-body tick species. We 
report 46 cases of B. miyamotoi infection in humans and 
compare the frequency and clinical manifestations of this 
infection with those caused by B. garinii and B. burgdorferi 
infection. All 46 patients lived in Russia and had inﬂ  uenza-
like illness with fever as high as 39.5°C; relapsing febrile 
illness occurred in 5 (11%) and erythema migrans in 4 
(9%). In Russia, the rate of B. miyamotoi infection in Ixodes 
persulcatus ticks was 1%–16%, similar to rates in I. ricinus 
ticks in western Europe and I. scapularis ticks in the United 
States. B. miyamotoi infection may cause relapsing fever 
and Lyme disease–like symptoms throughout the Holarctic 
region of the world because of the widespread prevalence 
of this pathogen in its ixodid tick vectors.
B
orrelia miyamotoi, discovered in Japan in 1995, belongs 
to the relapsing fever group of Borrelia (1). Relapsing 
fever borreliae infections are characterized by inﬂ  uenza-
like illness and >1 relapse episode of bacteremia and fever. 
B. miyamotoi is more distantly related to B. burgdorferi, 
a group of spirochetes that includes B. burgdorferi s.l. 
strains (B. afzelii; B. garinii; and B. burgdorferi s.s., the 
causative agent of Lyme disease) (2,3). In Eurasia and 
North America, B. miyamotoi is found in a small percentage 
of all species of ixodid tick vectors of B. burgdorferi, 
including  Ixodes persulcatus ( 1,3,4),  I. ricinus ( 5–7),  I. 
scapularis (2,3,8,9), and I. paciﬁ  cus (10). It is transmitted 
transovarially and transstadially by ticks and coexists with 
B. burgdorferi (2,3). Recently, we discovered B. miyamotoi 
in I. persulcatus and I. ricinus ticks in the European and 
Asian regions of Russia. In these areas, human ixodid tick-
borne infections, including those caused by B. afzelii, B. 
garinii, and viral tick-borne encephalitis virus (TBEV; 
genus Flavivirus) are endemic and transmitted by the same 
tick species. 
Despite the presence of B. miyamotoi in vector 
ticks, to our knowledge, human disease caused by this 
spirochete has not been deﬁ   nitively established. We 
previously noted presumptive B. miyamotoi infection in 
residents of central Russia with inﬂ  uenza-like illness but 
were uncertain whether their clinical manifestations were 
caused by co-infecting B. burgdorferi s.l. species (11–13). 
To conﬁ  rm those ﬁ  ndings and develop initial estimates of 
the prevalence and severity of B. miyamotoi infection, we 
conducted a comparative cohort study. We used improved 
antibody assays and PCRs to compare the relative frequency 
and clinical manifestations of B. miyamotoi infection with 
those of B. garinii infection in Russia and B. burgdorferi 
infection in the United States.
Methods
Study Design
We enrolled patients admitted to Municipal Clinical 
Hospital No. 33 in Yekaterinburg City, Russia, from May 19 
through August 25, 2009, for suspected tick-borne infection. 
Yekaterinburg is in the Asian part of Russia, ≈1,200 miles 
east of Moscow. Viral tick-borne encephalitis and acute 
borreliosis are highly endemic to this region. Patients with 
moderate or severe disease are usually hospitalized.
We compared the clinical characteristics of patients 
experiencing laboratory-conﬁ  rmed B. miyamotoi infection 
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with those of patients experiencing B. garinii infections 
from the same area and with those of patients who 
experienced B. burgdorferi infection in the northeastern 
United States. The US data came from a tick-borne 
diseases study conducted during 1991–2008 (14,15). For 
each patient at all study sites, we recorded the presence or 
absence of a standard set of 11 clinical manifestations. All 
patients signed an informed consent form in accordance 
with the institutional review boards of the Municipal 
Clinical Hospital in Yekaterinburg City or the University 
of Connecticut School of Medicine.
We also determined the frequency of B. garinii, B. 
afzelii, B. burgdorferi, and B. miyamotoi in I. persulcatus 
and I. ricinus ticks in Yekaterinburg and several additional 
regions of Russia (Figure 1). Ticks were collected by drag 
cloth, visually identiﬁ  ed to species level, and analyzed by 
PCR to identify speciﬁ  c Borrelia species.
Case Deﬁ  nitions
Diagnosis of B. miyamotoi infection required the report 
of a tick bite, presence of clinical manifestations consistent 
with borreliosis, and laboratory evidence of B. miyamotoi 
infection. Clinical manifestations included fever, headache, 
chills, fatigue, vomiting, and myalgia. Conﬁ  rmation  of 
active infection consisted of ampliﬁ  cation of B. miyamotoi 
DNA/RNA in blood by species-speciﬁ  c PCR and detection 
of anti-borreliae immunoglobulin (Ig) M in acute- and/or 
convalescent-phase serum samples.
In Russia, diagnosis of B. garinii infection required 
report of a tick bite, physician diagnosis of erythema 
migrans (EM; an expanding, ring-like erythematous rash >5 
cm in diameter), or an inﬂ  uenza-like illness. Conﬁ  rmation 
of infection consisted of ampliﬁ  cation  of  B. garinii 
DNA/RNA in blood by speciﬁ  c PCR, followed by direct 
sequencing of 5S-23S ribosomal RNA (rRNA) intergenic 
spacers, and detection of anti-borreliae IgM in acute- and/
or convalescent-phase serum samples.
In the United States, diagnosis of B. burgdorferi 
infection required a physician’s diagnosis of EM or an 
inﬂ  uenza-like illness. For all cases, conﬁ  rmation of infection 
consisted of a >4-fold increase in anti–B. burgdorferi 
antibody in acute- and convalescent-phase serum samples. 
The diagnosis of TBEV infection was based on a viral-like 
illness, including headache (with or without meningitis or 
encephalitis), ampliﬁ  cation of TBEV RNA in blood by 
species-speciﬁ  c PCR, and/or detection of anti-TBEV IgM 
in an acute-phase serum sample.
Laboratory Assays
PCR
The PCR we used enabled detection of DNA and 
RNA sequences. DNA/RNA was extracted from 2 mL of 
whole venous blood with EDTA or from tick suspensions 
by using an AmpliSens Riboprep Kit (Central Institute 
of Epidemiology, Moscow, Russia) according to the 
manufacturer’s instructions. Of the blood samples used for 
PCR, 81% were obtained at the time of hospital admission 
and 96% within 2 days of admission. To assay the inhibitory 
effect of blood and tick extracts on the PCR, all samples 
were spiked with a universal RNA recombinant control 
having a known number of RNA copies per milliliter. 
Reverse transcription of RNA to cDNA was performed 
by using an Amplisens Reverta-L Kit (Central Institute of 
Epidemiology). The cDNA samples were assayed for B. 
miyamotoi and other tick-borne pathogens by using real-
time quantitative PCR (qPCR) assays in a Rotor Gene 6000 
cycler (Corbett Life Science, Concorde, New South Wales, 
Australia).
The cDNA samples were divided into 2 aliquots, and 
different types of real-time qPCR were performed on each. 
The ﬁ  rst used in-house primers and a probe that targeted 
the 16S rRNA gene of B. miyamotoi. The inclusion of the 
reverse transcription procedure improved the detection 
sensitivity because the 16S rRNA that also became 
detectable is present in higher copy numbers than the 16S 
rRNA gene. The detection limit of at least 5 × 103 copies/
mL was determined by using positive recombinant DNA of 
the B. miyamotoi 16S rRNA gene fragment with a known 
number of copies. The B. miyamotoi–speciﬁ  c forward and 
reverse primers at 360 nmol/L were, respectively, Brm1 
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Figure 1. Percentage of Ixodes persulcatus (I. p.) and I. ricinus 
(I. r.) ticks infected with Borrelia miyamotoi in Russia. The number 
of ticks that were tested is given in parenthesis. Star indicates study 
location of human B. miyamotoi infection.RESEARCH
5′-CGCTGTAAACGATGCACACTTGGTGTTAATC-3′ 
and Brm2 5′-CGGCAGTCTCGTCTGAGTCCCCAT
CT-3′. The corresponding dye-labeled probe (ﬁ  nal 
concentration 100 nmol/L) was R6G-CCTGGGGA
GTATGTTCGCAAGAATGAAACTC-BQH1. The PCR 
conditions were 95°C for 15 min; followed by 10 cycles at 
95°C for 20 s, 67°C for 50 s, and 72°C for 20 s; then by 40 
cycles at 95°C for 20 s, 60°C for 50 s, and 72°C for 20 s. 
The ﬂ  uorescence signal was recorded at the 60°C step for 
the last 40 cycles. Each run included negative controls and 
positive recombinant control DNA of the B. miyamotoi 16S 
rRNA gene fragment as a standard. PCR-based detection of 
B. burgdorferi s.l., Anaplasma phagocytophilum, Ehrlichia 
chaffeensis, Ehrlichia muris, and TBEV was performed 
on the second cDNA aliquot by using a commercial 
multiplex PCR (AmpliSens TBEV, B. burgdorferi 
s.l., A. phagocytophillum, E. chaffeensis/E. muris-FL; 
Central Institute of Epidemiology) (16), according to the 
manufacturer’s instructions. This assay was designed 
to detect, but not discriminate between, B. afzelii,  B. 
burgdorferi s.s., and B. garinii. The same assays were used 
to detect speciﬁ  c DNA/RNA in ticks and humans.
The speciﬁ  city of B. miyamotoi and B. burgdorferi s.l. 
assays was conﬁ  rmed by direct sequencing of ﬂ  agellin gene 
fragments and/or 16S rRNA gene fragments and/or 5S-23S 
rRNA intergenic spacer ampliﬁ  ed from blood samples of the 
same patients or from the same ticks (GenBank accession 
nos. GU797331–GU797350, JF951378–JF951392). Of the 
97 borreliae sequenced, results of DNA ampliﬁ  cation using 
species-speciﬁ   c PCR were entirely consistent with the 
sequencing results. Absence of false-positive PCR results 
means that our PCRs were highly speciﬁ  c. 
Ampliﬁ   cation and further direct sequencing 
of the B. miyamotoi  ﬂ   agellin gene were performed 
by using degenerate primers FLA120F 5′-AGA
ATTAATMGHGCWTCTGATGATG-3′ and FLA920R 
5′-TGCYACAAYHTCATCTGTCATT-3′ (2,5). The 16S 
rRNA gene fragment was ampliﬁ   ed and sequenced 
by using 2 primers pairs: ﬁ   rst Bf1 5′-GCTGG
CAGTGCGTCTTAAGC-3′ and Brsp2 5′-CCTTACACC
AGGAATTCTAACTTCCYCTAT-3′, second Brsp1 5′-GG
GGTAAGAGCCTACCAAGGCTATGATAA-3′ and Br1 
5′-GCTTCGGGTACTCTCAACTC-3′ ( 5). Borrelial 
5S-23S rRNA intergenic spacer was ampliﬁ  ed  and 
sequenced by using nested PCR with outer primers pairs 
IGSa 5′-CGACCTTCTTCGCCTTAAAGC-3′ and IGSb 
5′-AGCTCTTATTCGCTGATGGTA-3′ and inner primers 
pair IGSe 5′-CCTTAAAGCTCCTAGGCATTCACCA-3′ 
and IGSd 5′-CGCGGGAGAGTARGTTATTGCGA-3′ 
(17). Nucleotide sequences were aligned, compared, and 
analyzed by using MEGA4.1 (www.megasoftware.net), 
ClustalW (www.clustal.org), and BLAST (www.ncbi.nlm.
nih.gov/blast/Blast.cgi).
ELISA 
Serum samples collected at the time of admission and 
1–2 weeks later were tested for anti-borrelial IgM and IgG. 
Serologic evidence of exposure to borreliae was detected 
by ELISA EUROIMMUN EI 2132–9601 M and EI 2132–
9601–2 G (EUROIMMUN AG, Lübeck, Germany). The 
ELISA consisted of a mixture of whole antigens from 
B. afzelii, B. burgdorferi, and B. garinii and thus could 
detect but not discriminate speciﬁ  c antibody against any of 
these species. Seroconversion in patients infected with the 
relapsing fever borrelia B. persica also has been detected 
by EUROIMMUN assay (18). Serum from most B. 
miyamotoi–positive patients reacted to the antigen(s) in this 
assay. Anti-TBE IgM was detected by the semiquantitative 
EUROIMMUN ELISA EI 2661–9601 M.
Statistical Analyses
Comparisons were performed by using the Mann-
Whitney U test (independent numeric interval variables), 
χ2 test (categorical variables), and corresponding exact 
tests, if necessary; p<0.01 was statistically signiﬁ  cant. Data 




Among 302 patients evaluated for presumptive tick-
borne infection, B. miyamotoi infection was found for 51 
(17%) (Table 1). Of these 51 patients, anti-borrelial IgM 
was found at the time of admission for 6, anti-borrelial IgM 
seroconversion was demonstrated 2 weeks after admission 
for 40, no such antibody was found for 2, and laboratory 
evidence of TBEV co-infection was found for 3. Only the 
46 patients who had ampliﬁ  able B. miyamotoi DNA and 
anti-borrelial IgM and who were not coinfected with TBEV 
were included in further analyses. For 18 of these patients, 
anti-borrelial IgG was absent at admission but detected 
2 weeks after admission; subsequent IgG testing was 
not performed because all patients had IgM by 2 weeks. 
Attempts to detect B. miyamotoi on standard Giemsa-
stained blood smears and in culture in 6 patients yielded 
negative results. These tests were performed 4–6 days after 
onset of illness but before initiation of antimicrobial drug 
therapy.
B. garinii infection was diagnosed for 21 (7%) 
patients, all of whom had ampliﬁ  able  B. garinii DNA/
RNA (GenBank accession nos. GU797347, GU797348, 
GU797349, GU797350) and anti-borreliae IgM in their 
blood. EM was found on all but 2 B. garinii–infected 
patients.
Of the remaining 230 patients, 83 had apparent B. 
burgdorferi s.l. infection (59 had EM and anti-borreliae IgM 
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in acute- and/or convalescent-phase serum, and 24 had EM 
alone); 42 had unconﬁ  rmed Borrelia spp. infections with 
anti-borreliae IgM but lacked EM and were Borrelia spp. 
negative on PCR; 41 had TBE; 37 had fever of unknown 
origin after tick bite; and 27 had other diagnoses, including 
enteroviral infection, mononucleosis, or pyelonephritis. 
None of the 302 patients had any PCR-based evidence of 
B. afzelii, A. phagocytophillum, or E. muris infection.
Clinical Manifestations
Patients from Russia with B. miyamotoi and B. garinii 
infection and patients from the United States with B. 
burgdorferi infection were similar in age and sex. Time 
from tick bite to onset of symptoms was longer and time 
from symptom onset to hospital admission was shorter for 
B. miyamotoi patients than for B. garinii patients (Table 2).
More systemic manifestations, including fever and 
headache, were reported for B. miyamotoi patients than for 
B. garinii and B. burgdorferi patients (Table 3). Maximum 
temperatures measured at home and in the hospital were 
higher for B. miyamotoi patients (39.0°C, interquartile 
range [IQR] 38.8–39.5°C) than for B. garinii patients 
(37.6°C, IQR 38.8–39.5°C; p<0.001). Duration of fever 
was relatively short and did not differ signiﬁ  cantly for B. 
miyamotoi and B. garinii patients (3.4 ± 1.4 and 3.3 ± 2.8 
days, respectively). Body temperature began to return to 
reference range before antimicrobial drug therapy was 
initiated, as has been described for relapsing fever patients, 
in all but 1 B. miyamotoi patient. Hospital stay was longer 
for B. miyamotoi patients (median 20 days, IQR 15–22 
days) than for B. garinii patients (median 10 days, IQR 
10–13 days; p<0.001).
Although mean peripheral leukocyte and platelet counts 
were lower for patients with B. miyamotoi than B. garinii 
infection, they were within the reference range. Proteinuria 
and transient elevation of serum alanine aminotransferase 
and aspartate aminotransferase concentrations were found 
for 3× more B. miyamotoi patients than B. garinii patients 
(51% and 68% vs. 15% and 20%, respectively, p<0.01), but 
no nephritis or hepatitis was clinically apparent. We found 
similar clinical and laboratory results when we omitted 
from analysis the 4 B. miyamotoi patients with EM who 
might have been co-infected with B. burgdorferi s.l.
Therapy and Clinical Outcome
Antimicrobial drug therapy for the B. miyamotoi 
patients was started ≈1 week after admission when IgM-
based serologic tests results conﬁ   rmed the diagnosis 
(median 7 days, IQR 6–10 days). Therapy consisted 
of ceftriaxone, 2 g intravenously every 24 hours for 2 
weeks (42 patients) or doxycycline 100 mg orally every 
12 hours for 2 weeks (2 patients). Two patients received 
no antimicrobial drug while hospitalized; 1 later received 
doxycycline at home, and the other was readmitted to 
the hospital for relapse and received ceftriaxone. Patients 
with B. garinii infection received doxycycline (71%) or 
ceftriaxone (29%) immediately after admission because 
diagnosis of borreliosis, based on presence of EM, was 
made at the time of admission. B. burgdorferi patients all 
received doxycycline, 100 mg orally every 12 hours, or 
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B. miyamotoi infection, confirmed  46 4 46 0 0 46 0
B. miyamotoi infection, unconfirmed  2 0 2 0 0 0 0
B. miyamotoi infection, TBEV co-infection  3 0 3 0 0 2 3
B. garinii infection, confirmed  21 19 0 21 0 21 0
B. burgdorferi s.l. infection  83 83 0 0 0 59 0
Borrelia spp. infection, unconfirmed  42 0 0 0 0 42 0
TBEV infection, confirmed  21 0 0 0 5 0 21
TBEV, B. burgdorferi s.l. co-infection  9 9 0 0 2 ND  9
TBEV, Borrelia spp. co-infection  11 0 0 0 3 11 11
Other inflammatory disease  64 0 0 0 0 0 0
*TBEV, tick-borne encephalitis virus; Ig, immunoglobulin; ND, not determined. 




Infection timeline, median no. days (IQR) 
Patient characteristics  Tick bite to symptom 
onset
Symptom onset to 
hospital admission  Median age, y (range)  Male sex, no. (%) 
B. miyamotoi 46 54 (21–77)  24 (52)  15 (12–16)  1 (1–2) 
B. garinii 21 58 (18–87)  11 (52)  10 (7–13)†  5 (2–9)† 
B. burgdorferi 92 50 (14–79)  49 (53)  NA NA
*IQR, interquartile range; NA, not available. 
†p<0.001 in comparison with patients with B. miyamotoi infection. RESEARCH
amoxicillin, 500 mg orally every 8 hours, for 2–4 weeks. 
A Jarisch-Herxheimer reaction was noted for 7 (15%) of 
the 46 B. miyamotoi patients. More such reactions might 
have been expected if treatment had not been delayed until 
≈1 week after admission. A single course of ceftriaxone or 
doxycycline appeared to clear B. miyamotoi infection.
Relapsing Infection
Of the 46 B. miyamotoi patients, 5 (11%, 95% con-
ﬁ  dence interval 2%–20%) experienced relapse of febrile 
illness; 1 patient experienced 2 relapses before hospital 
admission, and 4 experienced 1 relapse after hospitalization 
but before the start of antimicrobial drug therapy. Thus, 
antimicrobial drugs might have prevented relapse in those 
who received this therapy. The mean time between relapses 
was 9 days (range 2 days to 2 weeks). The maximum fever 
and duration of illness did not differ signiﬁ  cantly for the 
ﬁ  rst and second episodes of illness (Figure 2). No clinical 
or laboratory ﬁ  ndings indicated other infections (including 
blood-borne, skin, neurologic, respiratory, cardiac, 
gastrointestinal, and urologic) or medical conditions that 
could account for these febrile episodes.
B. miyamotoi in Ticks
During 2004–2007, we found B. miyamotoi–infected 
I. persulcatus ticks in the regions where the human 
cases had been noted (11,13), namely, 0.9% of 442 ticks 
in Yekaterinburg and 6.4% of 394 ticks in Izhevsk. B. 
miyamotoi–infected I. persulcatus and I. ricinus ticks were 
found in regions where human cases have not yet been 
identiﬁ  ed (Figure 1). These ﬁ  ndings were conﬁ  rmed by 
direct sequencing of PCR DNA ampliﬁ  cation  products 
(GenBank accession nos. GU797336, GU797337, 
GU797338, GU797346, JF951378–JF951392).
Genetic Characteristics of B. miyamotoi
The nucleotide sequences of 16S rRNA and ﬂ  agellin 
gene fragments of all B. miyamotoi isolates from humans 
and I. persulcatus ticks were almost indistinguishable from 
the corresponding sequences of the prototype Japan HT-
31 strain (1) (Figure 3). B. miyamotoi from I. ricinus ticks 
collected in the European part of Russia were more closely 
related to European B. miyamotoi strains (5,6).
Discussion
We provide conﬁ  rmatory evidence of B. miyamotoi 
infection in humans. Most patients experienced clinical 
manifestations similar to those caused by B. burgdorferi s.l. 
and relapsing fever Borrelia infections, a ﬁ  nding consistent 
with the genetic characteristics of this novel spirochete. 
Febrile relapses occurred in only 1 of 10 B. miyamotoi 
patients, 2 days to 1 month after the initial illness; however, 
early treatment may have prevented subsequent relapse for 
other patients. Although the febrile episodes at home might 
have been caused by other illnesses, the onset of fever within 
2 weeks after a tick bite was consistent with the incubation 
period of infection with borreliae. Furthermore, no clinical 
or laboratory ﬁ  ndings indicated other infections or medical 
conditions that could account for the febrile episodes. EM 
was found in ≈1 of 10 B. miyamotoi patients, but these 
patients might have had unrecognized B. burgdorferi s.l. 
co-infection. A single course of ceftriaxone or doxycycline 
seemed to clear B. miyamotoi infection. Although effective 
therapy is available, appropriate diagnosis and therapy are 
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Table 3. Clinical manifestations in patients with Borrelia spp. infection, Yekaterinburg City, Russia, 2009, and northeastern United 
States, 1991–2008* 
Manifestation














 EM 9 91 89 <0.001 <0.001 >0.999
 Multiple  EM 0 14 7 0.03 0.18 0.36
 Fever† 98 67 32 0.001 <0.001 0.005
 Fatigue 98 86 74 0.09 <0.001 0.4
 Headache 89 57 63 0.007 0.001 0.63
 Chills 35 10 43 0.04 0.36 0.005
 Myalgia 59 52 63 0.8 0.71 0.46
 Arthralgia 28 29 62 >0.999 <0.001 0.007
 Nausea 30 10 24 0.07 0.420 0.24
 Vomiting 7 5 7 >0.999 >0.999 >0.999
 Neck  stiffness 2 0 38 >0.999 <0.001 <0.001
Overall
  No. symptoms, mean ± SD  4.5 ± 1.4  4.2 ± 2.0  5.0 ± 2.3  0.43 0.13 0.13
  No. symptoms (excluding EM  
  and multiple EM), mean ± SD 
4.5 ± 1.4  3.1 ± 1.9  4.1 ± 2.3  0.007  0.46 0.09
*EM, erythema migrans. 
†Maximum axillary temperature >37.2°C for patients in Russia and maximum oral temperature >37.7°C for patients in the United States. Humans Infected with Borrelia miyamotoi
complicated by lack of awareness of B. miyamotoi as a 
human pathogen, the nonspeciﬁ  c symptoms of infection, 
and the absence of standardized and widely available 
assays. We found no PCR-based evidence of infection 
caused by B. afzelii, A. phagocytophilum, or E. muris in 
the patients, although these pathogens have been detected 
in Ixodes spp. ticks in the same region (16). There is only 
anecdotal evidence of B. afzelii infection conﬁ  rmed  by 
culture or PCR in Russia and none in the Yekaterinburg 
region. Relapsing fever borreliae other than B. miyamotoi 
were not found in Yekaterinburg.
B. miyamotoi infection may cause substantial health 
problems in the regions of Russia where it has been found, 
given its relatively high incidence and associated severity 
of disease. On the basis of the number of patients with B. 
miyamotoi infection in Yekaterinburg Hospital in 2009 and 
the populations of Yekaterinburg Province (4,395,000), 
we estimate that the minimal incidence of B. miyamotoi 
infections is 1 case per 100,000 population. According to 
ofﬁ  cial federal notiﬁ  cation during the past 10 years, ≈8,000 
cases of human borreliosis occur in Russia annually (12). 
B. miyamotoi infection seems to constitute at least 1/4 of 
all clinical tick-borne borreliosis cases in Yekaterinburg. 
If other Borrelia spp.–endemic areas have a similar rate 
of B. miyamotoi infection as Yekaterinburg (and our tick 
data suggest that this assumption is reasonable), >1,000 B. 
miyamotoi cases might occur in Russia each year. More 
studies are necessary to determine if this projection is 
accurate.
Acute  B. miyamotoi infection was more severe 
than early stage B. burgdorferi infection. The time from 
symptom onset to hospital admission was shorter, and 
the number of clinical manifestations was greater for 
patients with B. miyamotoi infection than with B. garinii 
infection. Relapsing febrile episodes were only reported 
for B. miyamotoi patients. Such multiple disease episodes 
not only have an adverse effect on a patient’s health but 
also may result in costly medical bills, many days or 
weeks of lost wages, and medical misdiagnosis (19–22). 
Co-infection of B. miyamotoi with other ixodid tick–
transmitted agents may increase disease severity (15,23). 
Additional problems that might occur with B. miyamotoi 
infection are ocular, neurologic, respiratory, cardiac, and 
pregnancy complications associated with relapsing fever 
(19–22).
Our study had several limitations. Attempts to detect 
B. miyamotoi on blood smear or in culture were not 
successful, although we conﬁ  rmed B. miyamotoi infection 
with a combination of qPCR, genetic sequencing, clinical, 
and seroconversion evidence. The comparison of clinical 
manifestations of Borrelia spp. infection of patients from 
Russia and the United States was complicated by enrollment 
at different times and from different locations, although 
we assessed the same 11 clinical manifestations at each 
location. The possibility that the clinical description of our 
B. miyamotoi cases was compromised by unrecognized co-
infection with B. burgdorferi s.l. is unlikely. The expected 
number of cases of co-infection depends on the prevalence 
of the pathogens in ticks in the region (3,11,24), and this 
number is even fewer than the 4 B. miyamotoi patients with 
EM we found. Inclusion or exclusion of these 4 cases had 
no effect on our comparative analysis with patients who did 
not have B. miyamotoi infection. We limited our description 
of B. garinii cases to those that were conﬁ  rmed by detection 
of ampliﬁ  able B. garinii DNA/RNA, although such cases 
may be more severe than those in which such DNA/RNA 
cannot be detected (25,26). Patients with B. burgdorferi s.l. 
PCR–negative results experienced fewer symptoms and 
milder fever than did patients with B. burgdorferi s.l. PCR–
positive results. Our analysis of patients with B. miyamotoi 
and B. garinii infection was limited to those who were 
hospitalized, although hospital admission policy in these 
regions of Russia is liberal because of concern about TBE 
and problems associated with B. burgdorferi infection.
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Figure 2. Examples of relapsing fever episodes in 2 patients with 
Borrelia miyamotoi infection. Arrows indicate the timing of tick bite, 
hospital admission, PCR testing, anti-borreliae immunoglobulin (Ig) 
M testing, and initiation of antimicrobial drug therapy.RESEARCH
The geographic dispersion and extent of B. miyamotoi 
disease in humans are unclear, but the infection probably 
occurs outside of Russia, given the comparative infection 
rates of vector ticks in Russia and at several locations in 
Europe and the United States (2–8). In the northeastern 
United States, ≈15% of all spirochetes carried by I. 
scapularis ticks are B. miyamotoi (2). Cases may remain 
undiagnosed because of the nonspeciﬁ   c nature of the 
illness, which might be confused with viral infections or 
such tick-borne infections as Lyme disease, babesiosis, 
anaplasmosis, or ehrlichiosis, and because of the lack of 
laboratory tests for conﬁ  rmatory diagnosis (19–22). 
B. miyamotoi infection may have negative health 
consequences, including relapsing disease that may last for 
months and may not respond to inappropriate antimicrobial 
drug therapy. The discovery of a Borrelia sp. that is 
pathogenic in humans and transmitted by an array of ixodid 
ticks greatly expands the potential geographic distribution 
of this disease (1–11). Further investigation of possible B. 
miyamotoi infection in humans is warranted wherever I. 
paciﬁ  cus, I. persulcatus, I. ricinus, and I. scapularis ticks 
are found.
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Figure 3. Phylogenetic tree of Borrelia spp. detected in persons and ticks, based on ﬂ  agellin gene fragment (A) and16S rRNA gene fragment 
(B). Sequences were aligned and analyzed by using MEGA4.1 software (www.megasoftware.net). Genetic trees were constructed from 
the partial nucleotide sequences of the ﬂ  agellin gene and the 16S rRNA gene by using the Kimura 2-parameter model and the unweighted 
pair group method with arithmetic mean. Arrow indicates the 16 Borrelia spp. from Yekaterinburg in 2009 that had the same nucleotide 
sequence. Circles indicate sequences that we listed in GenBank (accession nos. GU797331–GU797346 and JF951378–JF951392). 
Sequences for B. burgdorferi sensu lato and relapsing fever borreliae are shown for comparison. Scale bars indicate genetic distance.Humans Infected with Borrelia miyamotoi
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